Literature DB >> 7637012

Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.

S Tang1, B Patterson, J A Levy.   

Abstract

Previous studies have suggested that resting CD4+ lymphocytes can be infected by human immunodeficiency virus (HIV), but viral production is inhibited. If these cells are activated, progeny virions are released. The present data indicate that CD4+ lymphocytes in the G0/G1 stage of the cell cycle which have been highly purified to remove macrophages and activated HLA-DR+ cells can also be infected by HIV. However, our findings differ from those of earlier reports since in this study, infected quiescent CD4+ cells cannot be activated to produce virus after virus inoculation. PCR analyses indicate that reverse transcription in these CD4+ cells is arrested at a very early step in proviral DNA formation (U3-R region). They do not show any evidence of longer DNA transcripts (e.g., U3-gag). When these quiescent infected CD4+ lymphocytes are activated by exposure to mitogens and macrophages and then reinoculated with HIV, the replication of virus takes place. Resting CD4+ lymphocytes are also resistant to infection when they are cocultured with HIV-infected macrophages. Only activated CD4+ cells are susceptible to cell-to-cell transmission. These observations suggest that in vivo tissue macrophages, susceptible to HIV replication, are the major cells initially productively infected by the virus. Then these cells can transfer HIV to activated CD4+ lymphocytes with resultant virus production. The presence of arrested reverse transcription in quiescent cells raises questions about the cellular factors required to permit production of longer HIV proviral DNA copies. Because they can be reinfected once they have been activated, these infected quiescent cells could be a source of recombinant viruses in the host.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637012      PMCID: PMC189423     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes.

Authors:  S D Gowda; B S Stein; N Mohagheghpour; C J Benike; E G Engleman
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

2.  Inactivation of HIV-1 by trypsin and its use in demonstrating specific virus infection of cells.

Authors:  S B Tang; J A Levy
Journal:  J Virol Methods       Date:  1991-06       Impact factor: 2.014

3.  CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Authors:  C E Mackewicz; H W Ortega; J A Levy
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

Review 4.  Accessory cell signals involved in T-cell activation.

Authors:  T D Geppert; L S Davis; H Gur; M C Wacholtz; P E Lipsky
Journal:  Immunol Rev       Date:  1990-10       Impact factor: 12.988

5.  The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.

Authors:  J Homsy; M Meyer; M Tateno; S Clarkson; J A Levy
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

6.  MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency virus (HIV).

Authors:  M Tateno; J A Levy
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

7.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

8.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions.

Authors:  A D Hoffman; B Banapour; J A Levy
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

9.  HIV-1 replication is controlled at the level of T cell activation and proviral integration.

Authors:  M Stevenson; T L Stanwick; M P Dempsey; C A Lamonica
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus.

Authors:  T M Folks; D Powell; M Lightfoote; S Koenig; A S Fauci; S Benn; A Rabson; D Daugherty; H E Gendelman; M D Hoggan
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

View more
  30 in total

1.  Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.

Authors:  T Pierson; T L Hoffman; J Blankson; D Finzi; K Chadwick; J B Margolick; C Buck; J D Siliciano; R W Doms; R F Siliciano
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Tat protein induces self-perpetuating permissivity for productive HIV-1 infection.

Authors:  C J Li; Y Ueda; B Shi; L Borodyansky; L Huang; Y Z Li; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 3.  Quiescent T cells and HIV: an unresolved relationship.

Authors:  Dimitrios N Vatakis; Christopher C Nixon; Jerome A Zack
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.

Authors:  J Y Zhou; D C Montefiori
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals.

Authors:  D J Blackbourn; C E Mackewicz; E Barker; T K Hunt; B Herndier; A T Haase; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Highly purified CD25- resting T cells cannot be infected de novo with HIV-1.

Authors:  C S Chou; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

7.  Reverse transcription complex: the key player of the early phase of HIV replication.

Authors:  Sergey Iordanskiy; Michael Bukrinsky
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

8.  Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation.

Authors:  L A Pinto; V Blazevic; B K Patterson; C Mac Trubey; M J Dolan; G M Shearer
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells.

Authors:  R E Sutton; H T Wu; R Rigg; E Böhnlein; P O Brown
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

Authors:  A M Caliendo; A Savara; D An; K DeVore; J C Kaplan; R T D'Aquila
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.